TARS - Tarsus Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Irvine,
United States
Type: Equity
TARS price evolution
TARS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $224.95 | $226.67 | $106.77 | $66 |
| Short term investments | $2.5 | $20.21 | $71.45 | $135.22 |
| Net receivables | $17.71 | $6.37 | $0.25 | $2.92 |
| Inventory | $3.11 | $0.01 | ||
| Total current assets | $256.13 | $259.28 | $183.48 | $208.65 |
| Long term investments | $0.63 | $0.21 | $0.32 | $0.31 |
| Property, plant & equipment | $3.35 | $3.63 | $3.68 | $1.73 |
| Goodwill & intangible assets | $3.87 | $3.97 | ||
| Total noncurrent assets | $9.36 | $9.05 | $5.45 | $2.57 |
| Total investments | $3.13 | $20.42 | $71.78 | $135.53 |
| Total assets | $265.49 | $268.33 | $188.93 | $211.21 |
| Current liabilities | ||||
| Accounts payable | $23.69 | $15.35 | $9.46 | $9.05 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $36.94 | $23.25 | $14.77 | $13.26 |
| Long term debt | $29.82 | $29.71 | $24.61 | $24.52 |
| Total noncurrent liabilities | $31.57 | $31.42 | $26.43 | $24.55 |
| Total debt | $29.82 | $29.71 | $24.61 | $24.52 |
| Total liabilities | $68.5 | $54.67 | $41.2 | $37.81 |
| Shareholders' equity | ||||
| Retained earnings | -$244.66 | -$202.75 | -$163.61 | -$132.18 |
| Other shareholder equity | -$0 | -$0.01 | -$0.02 | -$0.07 |
| Total shareholder equity | $196.99 | $213.66 | $147.73 | $173.4 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $224.95 | $71.66 | $171.33 | $168.15 |
| Short term investments | $2.5 | $145.37 | $0.48 | |
| Net receivables | $17.71 | $3.58 | $0.09 | $0.02 |
| Inventory | $3.11 | |||
| Total current assets | $256.13 | $225.38 | $175.95 | $170.7 |
| Long term investments | $0.63 | $0.37 | ||
| Property, plant & equipment | $3.35 | $1.53 | $1.83 | $1.2 |
| Goodwill & intangible assets | $3.87 | |||
| Total noncurrent assets | $9.36 | $2.49 | $2.96 | $1.32 |
| Total investments | $3.13 | $145.74 | $0.48 | |
| Total assets | $265.49 | $227.86 | $178.91 | $172 |
| Current liabilities | ||||
| Accounts payable | $23.69 | $9.91 | $2.86 | $2.2 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $36.94 | $15.43 | $11.48 | $5.4 |
| Long term debt | $29.82 | $19.43 | ||
| Total noncurrent liabilities | $31.57 | $19.53 | $0.7 | $0.6 |
| Total debt | $29.82 | $19.43 | ||
| Total liabilities | $68.5 | $34.96 | $12.18 | $6 |
| Shareholders' equity | ||||
| Retained earnings | -$244.66 | -$108.76 | -$46.67 | -$32.8 |
| Other shareholder equity | -$0 | -$0.07 | ||
| Total shareholder equity | $196.99 | $192.9 | $166.73 | $165.98 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $13.08 | $1.87 | $2.5 | |
| Cost of revenue | $1.22 | $0.38 | ||
| Gross Profit | $11.86 | $1.49 | $2.5 | |
| Operating activities | ||||
| Research & development | $13.3 | $12.11 | $12.55 | $12.36 |
| Selling, general & administrative | $43.01 | $30.32 | $20.27 | $15.1 |
| Total operating expenses | $56.31 | $42.43 | $32.82 | $27.45 |
| Operating income | -$44.45 | -$40.94 | -$32.82 | -$24.95 |
| Income from continuing operations | ||||
| EBIT | -$40.91 | -$38.29 | -$30.61 | -$22.73 |
| Income tax expense | ||||
| Interest expense | $0.99 | $0.86 | $0.81 | $0.68 |
| Net income | ||||
| Net income | -$41.9 | -$39.15 | -$31.42 | -$23.42 |
| Income (for common shares) | -$41.9 | -$39.15 | -$31.42 | -$23.42 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $17.45 | $25.82 | $57.03 | |
| Cost of revenue | $1.59 | $0.95 | $2.08 | |
| Gross Profit | $15.85 | $24.86 | $54.95 | |
| Operating activities | ||||
| Research & development | $50.31 | $42.62 | $41.71 | $18.83 |
| Selling, general & administrative | $108.7 | $44.95 | $25.4 | $8.17 |
| Total operating expenses | $159.01 | $87.57 | $67.11 | $27 |
| Operating income | -$143.16 | -$62.71 | -$12.16 | -$27 |
| Income from continuing operations | ||||
| EBIT | -$132.55 | -$59.9 | -$13.77 | -$26.62 |
| Income tax expense | -$0 | $0.06 | $0 | |
| Interest expense | $3.35 | $2.2 | $0.19 | |
| Net income | ||||
| Net income | -$135.89 | -$62.09 | -$13.83 | -$26.81 |
| Income (for common shares) | -$135.89 | -$62.09 | -$13.83 | -$26.81 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$41.9 | -$39.15 | -$31.42 | -$23.42 |
| Operating activities | ||||
| Depreciation | $0.48 | $0.37 | $0.32 | $0.26 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.48 | $5.25 | $5.19 | $3.91 |
| Total cash flows from operations | -$39.34 | -$32.36 | -$23.83 | -$21.97 |
| Investing activities | ||||
| Capital expenditures | -$4.38 | -$0.79 | -$0.34 | |
| Investments | $17.85 | $51.74 | $64.88 | $11.63 |
| Total cash flows from investing | $17.85 | $47.37 | $64.09 | $11.29 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $19.76 | $99.89 | $0.51 | $0.01 |
| Net borrowings | $5 | $5 | ||
| Total cash flows from financing | $19.76 | $104.89 | $0.51 | $5.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.73 | $119.9 | $40.78 | -$5.66 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$135.89 | -$62.09 | -$13.83 | -$26.81 |
| Operating activities | ||||
| Depreciation | $1.42 | $0.79 | $0.61 | $0.25 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.83 | $13.46 | $8.46 | $0.84 |
| Total cash flows from operations | -$117.49 | -$49.03 | $3.75 | -$21.14 |
| Investing activities | ||||
| Capital expenditures | -$5.5 | -$0.51 | -$0.59 | -$0.46 |
| Investments | $146.11 | -$144.12 | ||
| Total cash flows from investing | $140.6 | -$144.63 | -$0.59 | -$0.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $120.18 | $74.94 | $0.32 | $92.04 |
| Net borrowings | $10 | $19.13 | ||
| Total cash flows from financing | $130.18 | $93.99 | $0.02 | $131.77 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $153.29 | -$99.67 | $3.18 | $110.18 |
News
Fundamentals
| Market cap | $1.15B |
|---|---|
| Enterprise value | $958.13M |
| Shares outstanding | 34.21M |
| Revenue | $17.45M |
|---|---|
| EBITDA | -$131.13M |
| EBIT | -$132.55M |
| Net Income | -$135.89M |
| Revenue Q/Q | 30.76% |
| Revenue Y/Y | -32.42% |
| P/E ratio | -8.49 |
|---|---|
| EV/Sales | 54.92 |
| EV/EBITDA | -7.31 |
| EV/EBIT | -7.23 |
| P/S ratio | 66.10 |
| P/B ratio | 5.85 |
| Book/Share | 5.76 |
| Cash/Share | 6.58 |
| EPS | -$3.97 |
|---|---|
| ROA | -58.20% |
| ROE | -74.28% |
| Debt/Equity | 0.35 |
|---|---|
| Net debt/EBITDA | 1.19 |
| Current ratio | 6.93 |
| Quick ratio | 6.85 |